Engineered immune cells take on childhood blood cancers in early trial
NCT ID NCT06173518
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This early-phase trial is testing a new CAR T-cell therapy called AUTO1 (obe-cel) in up to 30 children with B-cell acute lymphoblastic leukemia or B-cell non-Hodgkin lymphoma that has returned or not responded to treatment. The therapy uses the child's own immune cells, which are modified in a lab to recognize and attack cancer cells. The main goals are to check safety and see how many children achieve complete remission within three months.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- AUTO1 (Obecabtagene autoleucel [Obe-cel]) - a type of CAR T-cell therapy made from the patient's own immune cells
- What this could lead to
- If successful, this could offer a new treatment option for children with hard-to-treat B-cell cancers that have come back or not responded to standard therapy.
- What could go wrong
- This is an early-phase trial with only 30 participants, so results may not apply to all patients. CAR T-cell therapy can cause serious side effects like cytokine release syndrome and low antibody levels.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for RELAPSED OR REFRACTORY B CELL ACUTE LYMPHOBLASTIC LEUKEMIA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Email: •••••@•••••
Locations
-
Children's Hospital of Philadelphia
RECRUITINGPhiladelphia, Pennsylvania, 19104, United States
-
Great North Children's Hospital
RECRUITINGNewcastle upon Tyne, United Kingdom
-
Great Ormond Street Hospital for Children NHS Foundation Trust
RECRUITINGLondon, United Kingdom
-
Hospital Nino Jesus
RECRUITINGMadrid, Spain
-
Hospital Vall d'Hebron
RECRUITINGBarcelona, Spain
-
Methodist Children's Hospital
RECRUITINGSan Antonio, Texas, 78229, United States
-
Primary Children's Hospital
RECRUITINGSalt Lake City, Utah, 84113, United States
-
Royal Manchester Children's Hospital
RECRUITINGManchester, United Kingdom
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Bispecific antibody shows promise for Hard-to-Treat lymphoma in Real-World study
- Engineered immune cells take aim at Hard-to-Treat childhood leukemia
- New pill targets Hard-to-Treat lymphoma in early human test
- New hope for tough lymphoma: experimental drug GSK5926371 enters human trials
- New hope for tough cancers: experimental drug LP-284 enters human testing
- Supercharged immune cells take on tough B-Cell cancers in early trial